The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment

CORC > 生态环境研究中心 > 中国科学院生态环境研究中心 > 城市与区域生态国家重点实验室

	The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment
	Wang, Lingjuan 2; Li, Xiaoqing ; Mu, Yanxi 1; Lu, Chang ; Tang, Shiqian ; Lu, Kun ; Qiu, Xiaoming ; Wei, Aili ; Cheng, Yongjiu 4; Wei, Wei
刊名	JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
	2019-12-01
卷号	56 页码:131-138
关键词	Ovarian cancer DFO CDDP Cancer therapy
ISSN号	0946-672X
英文摘要	Background: Cisplatin (CDDP) resistance remains a major obstacle for treatment of ovarian cancer. Iron contributes to the growth and reproduction of malignant cells, thus iron chalators can inhibit the growth of tumor cells by depleting the intracellular iron pool. The iron chelator, desferrioxamine (DFO), has performed anticancer in previous study. The aim of our study is to determine the correlation between iron-deprivation and tumor chemosensitivity in ovarian cancer. Methods: To investigate the prognostic value of ferritin light (FTL), ferroportin (FPN), hepcidin (HAMP) and divalent metal-ion transporter-1 (DMT1) in ovarian cancer, the Kaplan-Meier analysis and the Gene Expression Profiling Interactive Analysis (GEPIA) were used. The ovarian cancer cell lines (SKOV-3 and OVCAR-3) were exposed to a gradient concentration of DFO (10, 20, 50, 100, 200 mu M) and CDDP (1, 5, 10, 50,100 mu M) for 24 h. The protein expression of FTL was tested. The expression of cancer stem cell (CSC) markers, including Sox2, Nanog and C-myc, were downregulated with treatment of DFO. Also, the mamosphere formation and the plation of CD44(+/high)/CD133(+/high) and Aldehyde dehydrogenase (ALDH)(+/high) SKOV-3 cells were reduced after treatment for 7d. Furthermore, we detected the expression of p53, BCL-2, BAX, and caspase-8. Results: The survival analysis revealed that high expression of FTL, DMT1, HAMP, showed poor overall survival (OS) in ovarian cancer patients. Our combined data found that DFO could effectively inhibit CSCs, improve the resistance to chemotherapy, and significantly enhanced the efficacy of CDDP therapy in vitro in promoting apoptosis. Besides, targeting molecular targets, including BAX, BCL-2, p53 and caspase-8 could serve as the clinical biomarkers to evaluate the effects of ovarian cancer. It is reasonable to believe that DFO adjuvant therapy in combination with CDDP chemotherapy can promote the improvement of treatment response in ovarian cancer patients. Conclusion: Our research suggests the experimental evidence for DFO and CDDP as a new effective combination therapy to enhance the efficacy of chemical therapy in ovarian cancer.
内容类型	期刊论文
源URL	[http://ir.rcees.ac.cn/handle/311016/42474]
专题	生态环境研究中心_城市与区域生态国家重点实验室
作者单位	1.Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Reprod Hlth, Wuhan 430030, Hubei, Peoples R China 2.Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Gynecol, Beijing 100050, Peoples R China 3.Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China 4.Jinan Univ, Guangzhou Red Cross Hosp, Med Coll, Guangzhou 510220, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Wang, Lingjuan,Li, Xiaoqing,Mu, Yanxi,et al. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment[J]. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY,2019,56:131-138.
APA	Wang, Lingjuan.,Li, Xiaoqing.,Mu, Yanxi.,Lu, Chang.,Tang, Shiqian.,...&Wei, Wei.(2019).The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY,56,131-138.
MLA	Wang, Lingjuan,et al."The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment".JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY 56(2019):131-138.